Assessment of efficacy and impact on work productivity and attendance after a mandatory switch to generic second-generation antihistamines: Results of a patient survey in Norway

Clinical and Molecular Allergy

Volumn 9, Issue , 2011, Pages

  Thorn, Fredrik ^a   Celius, Halvor ^b   Ødegård, Tone ^b   Mandla, Randeep ^b   Hexeberg, Erik ^c  

^a Nordstrand Legesenter   (Norway)

^b MSD (Norge) A/S   (Norway)

^c Dr Hexeberg's Clinic   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; GENERIC DRUG; LORATADINE;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHRONIC URTICARIA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MANDATORY PROGRAM; NORWAY; PRODUCTIVITY; SOMNOLENCE; TREATMENT RESPONSE; WORK RESUMPTION;

EID: 79952051681     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/1476-7961-9-5     Document Type: Article

References (8)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, et al. World Health Organization; GA(2)LEN; AllerGen Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160. 10.1111/j.1398-9995.2007.01620.x, 18331513, World Health Organization; GA(2)LEN; AllerGen.
2. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, . Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443. 10.1111/j.1398-9995.2009.02178.x, 19772513, Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization.
3. Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria from four postmarketing surveillance studies. Clin Drug Invest 2010, 30:109-122.
4. Sugiura K, Hirai S, Suzuki T, Usuda T, Kondo T, Azumi T, Masaki S, Yokoi T, Nitta Y, Kamiya S, Ando K, Mori T, Tomita Y. Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria. Nagoya J Med Sci 2008, 70:97-106.
5. Glass DJ, Harper AS. Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract 2003, 4:10. 10.1186/1471-2296-4-10, 194638, 12917016.
6. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000, 22:760-769. 10.1016/S0149-2918(00)90009-2, 10929922.
7. Fretheim A, Johansen K. Vurdering av forskjeller i effekt mellom ulike annengenerasjons antihistaminer [Review on differences in efficacy between second-generation antihistamines] 2005, 3-39. Oslo, Norway: Norwegian Knowledge Centre for the Health Services.
8. Norwegian Medicines Agency Pharmaceutical pricing and reimbursement information 2008, 1-51. Norway Pharma Profile, Norwegian Medicines Agency.